Aadi Bioscience, Inc. (NASDAQ:AADI) Short Interest Update

Aadi Bioscience, Inc. (NASDAQ:AADI – Get Rating) was the target of a significant growth in short interest in February. As of February 28th, there was short interest totalling 1,180,000 shares, a growth of 6.3% from the February 13th total of 1,110,000 shares. Approximately 7.3% of the shares of the stock are sold short. Based on an average daily volume of 104,500 shares, the days-to-cover ratio is currently 11.3 days.

Institutional Trading of Aadi Bioscience

A number of hedge funds have recently added to or reduced their stakes in AADI. MetLife Investment Management LLC acquired a new position in Aadi Bioscience in the 4th quarter worth approximately $98,000. Annandale Capital LLC purchased a new position in shares of Aadi Bioscience during the 4th quarter worth $128,000. Alps Advisors Inc. raised its holdings in shares of Aadi Bioscience by 43.7% during the 4th quarter. Alps Advisors Inc. now owns 16,542 shares of the company’s stock worth $212,000 after acquiring an additional 5,033 shares during the period. Alerce Investment Management L.P. increased its position in shares of Aadi Bioscience by 26.0% during the 4th quarter. Alerce Investment Management L.P. now owns 1,630,830 shares of the company’s stock worth $20,924,000 after purchasing an additional 336,045 shares during the last quarter. Finally, Marshall Wace LLP acquired a new stake in shares of Aadi Bioscience during the 4th quarter worth about $199,000. 67.09% of the stock is owned by hedge funds and other institutional investors.

Aadi Bioscience Stock Performance

Shares of AADI opened at $7.52 on Friday. The company’s fifty day moving average is $11.29 and its 200 day moving average is $12.41. Aadi Bioscience has a fifty-two week low of $7.00 and a fifty-two week high of $20.09. The stock has a market capitalization of $183.49 million, a PE ratio of -2.52 and a beta of 1.25.

Aadi Bioscience Company Profile

(Get Rating)

Aadi Bioscience, Inc operates as a clinical-stage biopharmaceutical company. It develops precision therapies for genetically-defined cancers patients with mTOR pathway driver alterations such as alterations in TSC1 or TSC2 genes. The company was founded by Neil Desai on November 2007 and is headquartered in Los Angeles, CA.